Pharma
Hvivo raises full year sales and earnings guidance after ‘excellent’ start to 2023
The Dublin-headquartered pharmaceutical services company said it expects to generate full year sales of £55m and earnings margins of 19 per cent
Hvivo, the Irish pharmaceutical services company founded by businessman Cathal Friel, has increased its sales and profit guidance for 2023 after reporting double-digit growth for the first six months of the year.
On Tuesday, the Dublin-headquartered company reported a 52 per cent increase in half year sales to £27.3 million (€31.8 million) on the back of new contract wins to run clinical trials and human challenge studies on behalf of large pharma and biotech companies.
